In the first part, I’m sharing the latest update on value of academic vs. industry cell therapy trials. It measured as input – a number of registered clinical trials for the last 4 years, and, as output – a number of publications results of clinical studies. Take home message 1 – academics hugely outperform industry by number of cell therapy clinical studies and publications of their results.
In the second part, I highlighted differences between academic and industry models of development cell therapeutics. Take home message – these models are very different!
In the final part of the presentation, I discussed potential gaps in translation with emphasys on academic GMP cell therapy facilities. I described a few ways of interaction between academia and industry in translation of cell therapies. Finally I gave few advices to academics and industry folks on how to make translational interaction better.
You can look at, link to and cite the following graphs from the presentation:
Please feel free to discuss and share!